Michelle Werner

Michelle Werner, CEO of Alltrna and advocate for rare disease treatments, shares her journey from big pharma to biotech, fueled by her child's diagnosis. She explains the revolutionary potential of engineered tRNA therapy, emphasizing its ability to address countless rare genetic diseases. The conversation dives into the innovative use of AI for drug optimization and the challenges of using lipid nanoparticles for effective tRNA delivery. Michelle also highlights the importance of support networks for women leaders in biotech and the significance of storytelling in patient advocacy.

Join Michelle Werner, CEO of Alltrna, who focuses on engineered tRNA therapeutics for rare genetic diseases, and Mike Severino, CEO of Tessera Therapeutics, specializing in RNA-based gene-writing platforms. They discuss how 2026 is a pivotal year for clinical trials, share groundbreaking preclinical results, and explore innovative strategies for addressing genetic mutations. The duo also highlights the importance of patient advocacy and the adaptability of their platforms to tackle various genetic disorders, marking a promising future in genetic medicine.

Michelle Werner, CEO of Alltrna and CEO-Partner at Flagship Pioneering, discusses her transition from R&D to commercial in the biotech industry and the impact of business school. They dive into the potential of tRNA as a treatment modality, recent progress of Alterna, navigating capital markets, and being an authentic leader.